Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Jonathan R StrosbergPamela L KunzAndrew HendifarJames YaoDavid BushnellMatthew H KulkeRichard P BaumMartyn CaplinPhilippe RuszniewskiEbrahim DelpassandTimothy HobdayChris VerslypeAl BensonRajaventhan SrirajaskanthanMarianne PavelJaume MoraJordan BerlinEnrique GrandeNicholas ReedEttore SeregniGiovanni PaganelliStefano SeveriMichael MorseDavid C MetzCatherine AnsquerFrédéric CourbonAdil Al-NahhasEric BaudinFrancesco GiammarileDavid TaïebErik MittraEdward WolinThomas M O'DorisioRachida LebtahiChristophe M DerooseChiara M GranaLisa BodeiKjell ÖbergBerna Degirmenci PolackBeilei HeMaurizio F MarianiGermo GerickePaola SantoroJack L ErionLaura RavasiEric Krenningnull nullPublished in: European journal of nuclear medicine and molecular imaging (2020)
177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11.